Autoimmune neurology is evolving fast, as new antibodies and phenotypes are discovered. In this test-specific episode of the "Answers From the Lab" podcast, Anastasia Zekeridou, M.D., Ph.D., explains how updated testing improves Mayo Clinic Laboratories' screening of patients for three autoimmune neurology biomarkers: AMPA-R, IgLON5, and DPPX.

The AMPA receptor antibody, which is associated with encephalitis, is now known to exist in children and will be included in pediatric evaluations. IgLON5 and DPPX antibodies will be screened with more sensitive and specific cell- binding assays. IgLON5 — now known to be associated with amyotrophic lateral sclerosis (ALS)-like phenotype — will be added to Mayo Clinic Laboratories' axonal neuropathy evaluation.

"With these changes, patients are going to get relevant, accurate neural antibody testing faster and more efficiently. That's very important because these are treatable diseases," Dr. Zekeridou says.

The ability to provide added value through innovation rests on Mayo Clinic Laboratories' close relationship with clinicians. "We have a lot of clinicians in our laboratory. We also get feedback from our referring colleagues, our patients, and the literature," Dr. Zekeridou says. "It's impossible for clinicians — who often don't have insight into these methodologies — to keep up with all these changes. There needs to be trust in their relationship with the antibody referral lab."

Listen to learn more about Mayo Clinic Laboratories' AMPA-R, IgLON5, and DPPX testing updates.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

AIAES | Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum

ENC2 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

ENS2 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

PCDEC | Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Spinal Fluid

PCDES | Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum

The latest

Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.

June 11, 2024

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S.

June 4, 2024

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.

May 14, 2024

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

View MoreView Less